FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC

This article was originally published here

“We are pleased to offer people with certain types of lung cancer a new chemotherapy-free option that can help prolong their lives and be administered on a flexible

The post FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply